These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 988964)

  • 61. Potentiation by oral and intraperitoneal (+) sotalol and deoxysotalol of responses of rat uterus evoked by prostaglandin F2 alpha.
    Narendranath KA; Sharma PL
    Indian J Med Res; 1980 Sep; 72():441-4. PubMed ID: 7461775
    [No Abstract]   [Full Text] [Related]  

  • 62. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs.
    Garvey HL; Ram N
    J Pharmacol Exp Ther; 1975 Jul; 194(1):220-33. PubMed ID: 1151751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
    Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
    Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effects of oral sotalol on the conduction of accessory atrioventricular pathways].
    Blanc JJ; Boschat J; Ollivier JP; Penther P
    Arch Mal Coeur Vaiss; 1985 Jul; 78(7):1097-102. PubMed ID: 3929739
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pharmacoketics of the beta-adrenergic blockader sotalol].
    Schnelle K
    Verh Dtsch Ges Inn Med; 1974; 80():1535-8. PubMed ID: 4454476
    [No Abstract]   [Full Text] [Related]  

  • 67. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency.
    Berglund G; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1980 Oct; 18(4):321-6. PubMed ID: 7439252
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics of chlorpromazine in normal volunteers.
    Loo JC; Midha KK; McGilveray IJ
    Commun Psychopharmacol; 1980; 4(2):121-9. PubMed ID: 7428333
    [No Abstract]   [Full Text] [Related]  

  • 71. [Therapeutic indications for sotalol 160 mg].
    Ginestes J
    Ann Cardiol Angeiol (Paris); 1985 Jan; 34(1):45-52. PubMed ID: 2579609
    [No Abstract]   [Full Text] [Related]  

  • 72. A comparison of the cardiovascular effects of (+)-sotalol and (+/-)-sotalol following intravenous administration in normal volunteers.
    Johnston GD; Finch MB; McNeill JA; Shanks RG
    Br J Clin Pharmacol; 1985 Nov; 20(5):507-10. PubMed ID: 4074623
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.
    Jochemsen R; Wesselman JG; Hermans J; van Boxtel CJ; Breimer DD
    Br J Clin Pharmacol; 1983; 16 Suppl 2(Suppl 2):285S-290S. PubMed ID: 6661374
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of amiodarone after intravenous and oral administration.
    Andreasen F; Agerbaek H; Bjerregaard P; Gøtzsche H
    Eur J Clin Pharmacol; 1981 Mar; 19(4):293-9. PubMed ID: 7286032
    [No Abstract]   [Full Text] [Related]  

  • 75. Short-term myocardial uptake of d- and l-sotalol in humans: relation to hemodynamic and electrophysiologic effects.
    Ritchie RH; Sallustio BC; Hii JT; Horowitz JD
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):876-84. PubMed ID: 9641472
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of azapropazone following single oral and intravenous doses.
    Breuing KH; Gilfrich HJ; Meinertz T; Jähnchen E
    Arzneimittelforschung; 1979; 29(6):971-2. PubMed ID: 582795
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of ketanserin in patients with essential hypertension.
    Persson B; Pettersson A; Hedner T
    Eur J Clin Pharmacol; 1987; 32(3):259-65. PubMed ID: 3595699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of an intravenous microdialysis method for pharmacokinetic investigations in humans.
    Elshoff JP; Läer S
    J Pharmacol Toxicol Methods; 2005; 52(2):251-9. PubMed ID: 16125623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism.
    Funck-Brentano C; Silberstein DJ; Roden DM; Wood AJ; Woosley RL
    Br J Clin Pharmacol; 1990 Aug; 30(2):195-202. PubMed ID: 2169833
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Use of Intravenous Sotalol in Cardiac Arrhythmias.
    Samanta R; Thiagalingam A; Turner C; Lakkireddy DJ; Kovoor P
    Heart Lung Circ; 2018 Nov; 27(11):1318-1326. PubMed ID: 29853342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.